Treatment for teen substance use, explained.

When parents discover their teen has a substance use problem, the first thing they encounter online is usually a treatment program ad. The message is consistent: send your kid away, act now, before it's too late. The evidence tells a different story. Most adolescents with substance use disorders respond to outpatient, family-involved, evidence-based care — and the 2025 AACAP clinical practice guideline reflects that. This page is what actually works.

The 2025 AACAP guideline: what it recommends

The American Academy of Child and Adolescent Psychiatry published a clinical practice guideline in 2025 covering assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco). {CLINICAL REVIEW NEEDED} Its core recommendations for alcohol and drug problems:

• Motivational interviewing — a collaborative approach that helps adolescents explore their own reasons for change without confrontation
• Family therapy — approaches that engage parents directly, including behavioral family therapy and multidimensional family therapy
• Cognitive behavioral therapy (CBT) — addressing triggers, coping skills, and the thoughts and behaviors that sustain use
• Buprenorphine — for adolescents with opioid use disorder, as medication-assisted treatment {CLINICAL REVIEW NEEDED}

These are outpatient approaches. The guideline's existence is itself a corrective to the marketing narrative that adolescent substance problems require residential treatment.

Why family involvement is not optional

The treatment approaches with the strongest evidence for adolescents engage parents directly. This is different from adult treatment, where family involvement is sometimes optional.

For parents, this means treatment is something you do with your teen — attending sessions, learning communication strategies, changing household patterns that sustain use — not something you outsource by sending your kid away. {CLINICAL REVIEW NEEDED}

It also means that "tough love" approaches that cut off contact, impose isolation, or prioritize punishment over engagement are not evidence-based. They are, however, heavily marketed.

Buprenorphine for opioid use disorder

This section matters because it is badly underused and badly misunderstood.

{CLINICAL REVIEW NEEDED} Buprenorphine is a medication that reduces opioid cravings and withdrawal symptoms. For adolescents with opioid use disorder, the 2025 AACAP guideline supports its use as part of a comprehensive treatment plan. It reduces overdose risk and supports recovery.

Parents sometimes hear "medication for addiction" and think it means replacing one drug with another. That framing is wrong. Buprenorphine is treatment — the same way insulin is treatment for diabetes. It is not a moral failure to need it, and withholding it from an adolescent with opioid use disorder when it is clinically indicated costs lives. {CLINICAL REVIEW NEEDED}

Buprenorphine must be prescribed by a clinician with appropriate training. Not all pediatricians offer it; referral to an adolescent addiction specialist or opioid treatment program may be needed.

Outpatient vs. residential

Most adolescents with substance use problems do not need residential treatment as a first step. {CLINICAL REVIEW NEEDED} Outpatient care — weekly therapy, family sessions, medication management where indicated — is the appropriate starting point for the majority of cases.

Residential or intensive outpatient care may be appropriate when:

• There is acute safety risk that cannot be managed outpatient
• Severe substance use disorder has not responded to well-delivered outpatient care
• Co-occurring psychiatric conditions require intensive stabilization
• The home environment is actively dangerous or enabling in ways that cannot be addressed outpatient {CLINICAL REVIEW NEEDED}

Residential is not appropriate as a default, a punishment, or a response to a single positive drug test. The troubled-teen industry has built an entire marketing apparatus around sending kids away; the evidence does not support that as a first-line response for most adolescents. Read: The troubled teen industry.

For the full spectrum of care levels: Levels of care, explained.

Treating substance use and mental health together

Adolescent substance use rarely exists in isolation. Anxiety, depression, trauma, ADHD, and other conditions frequently co-occur — and often drove the use in the first place. {CLINICAL REVIEW NEEDED}

Treating substance use without addressing underlying mental health conditions tends to fail. Treating mental health without addressing substance use that interferes with medication and therapy also tends to fail. Integrated treatment — or closely coordinated care between an addiction specialist and a mental health clinician — produces better outcomes.

Cross-links: anxiety, depression.

How to find treatment

A practical starting sequence:

1. Talk to your teen's pediatrician. Be specific about what you've observed. Ask for referral to an adolescent addiction specialist.
2. Check your insurance. Outpatient substance use treatment is often covered; our insurance guide covers how to navigate it.
3. Use SAMHSA's treatment locator to find providers who treat adolescents — and verify they offer evidence-based approaches, not just 12-step groups.
4. Ask direct questions: What evidence supports your approach? Do you involve families? Do you prescribe buprenorphine for adolescents with opioid use disorder? What outcomes do you track?
5. Use our state guides for regulators, crisis lines, and coverage specifics where you live.

Hartley does not recommend specific programs. We describe what the evidence supports so you can evaluate what you're being sold.

What to be skeptical of

Red flags in adolescent substance use treatment marketing:

• "Act now before it's too late" urgency without clinical assessment
• Guaranteed outcomes or success rates without methodology
• Programs that refuse to involve parents or discourage family contact
• Wilderness therapy, boot camps, or "behavior modification" without evidence base
• Programs that prohibit or discourage medication for opioid use disorder
• High-pressure sales tactics, travel escorts, or enrollment coordinators who aren't clinicians

The investigative context: The troubled teen industry and How treatment programs market to parents.